Moderna's Cancer Vaccine May Cut Deaths In Half | The Brainstorm 146

Moderna's Cancer Vaccine May Cut Deaths In Half | The Brainstorm 146

August 26, 2026 · 27 min

About this episode

The episode discusses the promising results of a personalized mRNA cancer vaccine and its implications for oncology and technology disruption in the market.

In this episode of The Brainstorm, Sam, Nick, and Brett break down Merck and Moderna’s positive Phase 3 results for a personalized mRNA cancer vaccine, a treatment custom-built from each patient’s own tumor that cut mortality from advanced melanoma by roughly 50% versus the standard of care. The team digs into cost, manufacturing scale, and why the capital poured into mRNA during COVID may be paying off in oncology. Then Brett reports back from a weekend with Grok Bot, which recovered $75 of his wife’s forgotten escrow money on its first task, and the team debates why multiplayer agents could be the real threat to Microsoft’s enterprise moat. Key Points From This Episode: How a custom mRNA vaccine trains the immune system against a patient’s own tumor, and what Phase 3 melanoma results could mean for other cancers Why $200K–$300K per treatment limits early use, and what we believe has to change for personalized oncology to scale Why agents that live inside team chat, not one-on-one, may be the real disruption to Microsoft and Slack If you know ARK, you know we focus on long-term innovation. But that doesn’t mean we ignore breaking news. Every day, we debate the latest…

People in this episode

Hosts: Sam, Nick, Brett

Topics covered

Keywords

Mentioned in this episode

Organizations: Moderna, Merck, Microsoft, Slack, ARK, WOLF, Public

Products: mRNA cancer vaccine

More episodes of FYI - For Your Innovation

Explore listener stats, chart rankings, contacts and more on the FYI - For Your Innovation podcast page.